You are here

Technology Enabled Specialty Pharmacy for Oral Oncology

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43CA183141-01
Agency Tracking Number: R43CA183141
Amount: $224,751.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NCI
Solicitation Number: PA13-088
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
131 VARICK ST, STE 934
NEW YORK, NY 10013-1443
United States
DUNS: 803410542
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MICHAEL DAVIS
 (978) 631-1108
 michael.davis@medicasafe.com
Business Contact
 MICHAEL DAVIS
Phone: (978) 631-1108
Email: michael.davis@medicasafe.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): This SBIR Phase I application proposes development of the MedicaSafe ChemoCareRx, a technology- enabled specialty pharmacy service for oral oncology patients built around MedicaSafe's proprietary Medication Therapy Optimization (MTO) technology. The increased use of oral oncology chemotherapy regimens has led to a paradigm shift in the treatment of cancer. Patients are no longer required to receive treatment at infusion centers, but instead can complete treatments at home on their own. Although this new treatment option provides patients with increased flexibility and control, it also poses significan challenges and risks. With increased patient responsibility and reduced clinical oversight, treatment adherence and side-effect management have become major concerns for this patient population. As a result, specialty pharmacies focused specifically on oral oncolytics are becoming increasingly more common place in the U.S. and elsewhere. The goal of these programs are to

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government